Results 261 to 270 of about 11,024,988 (313)

Decade-long persistence of CD19 CAR T cells in B cell lymphomas. [PDF]

Nat Med
Paruzzo L, Chong ER, Chong EA, Zheng Z, Guruprasad P, Landsburg DJ, Nasta SD, Stella F, Ramasubramanian R, de Souza VB, Alkhatib MH, Ho M, Imparato A, Chen GM, Siegel DL, Plesa G, Dai A, Mackey S, Das P, Michener P, Jadlowsky J, Bushman FD, Patel V, Carturan A, Napier EB, Gonzalez VE, Jarocha D, Xu R, Levine BL, Porazzi P, Frey N, Porter DL, Svoboda J, Fraietta JA, June CH, Schuster SJ, Ruella M.   +36 more
europepmc   +1 more source

CAR-T Cells: Current Status, Challenges, and Future Prospects. [PDF]

MedComm (2020)
Adly AS, Cartron G, Adly AS, Egea JC, Dutilleul PC, Adly MS, Villalba M.   +6 more
europepmc   +1 more source

Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL. [PDF]

Acta Oncol
Fan J, Kutsch N, Heger JM, Gödel P, Heger E, Gruell H, Linde P, Ferdinandus S, Rosenbrock J, Dapper H, Fokas E, Borchmann P, Baues C.   +12 more
europepmc   +1 more source

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. [PDF]

Blood Adv
Aldoss I, Goldberg L, Zhang J, Artz A, Clark MC, Guan M, Espinosa R, Abimannan T, Wu J, Garcia B, Haas ER, Pathak KV, Lovell B, Pirrotte P, Agrawal V, Sanani N, Kasten S, Tilakawardane D, Wagner JR, Paul J, Shan H, Khaled S, Budde LE, Koller P, Stein AS, Pullarkat V, Salhotra A, Aribi A, Marcucci G, Wang X, Forman SJ.   +30 more
europepmc   +1 more source

The neurotoxic legacy of CAR-T cells: where do we stand? [PDF]

Ther Adv Neurol Disord
Pagliuca S, Jacquet C, Rubio MT, Sorrentino P.   +3 more
europepmc   +1 more source

CAR-T research

openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CAR T Cells

Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor, Zev A, Binder, Donald M, O'Rourke   +2 more
openaire   +2 more sources

CAR T Cells

2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire   +3 more sources

A Milestone for CAR T Cells

New England Journal of Medicine, 2017
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed ...
Eric, Tran, Dan L, Longo, Walter J, Urba
openaire   +2 more sources

Phenotyping of CAR T cells

2022
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire   +2 more sources